Journal of Gastric Cancer

The Korean Gastric Cancer Association (대한위암학회)
권호 표지
DOI QR코드

DOI QR Code

C-Kit-Negative Gastrointestinal Stromal Tumor in the Stomach

  • Seo, Ho Seok (Division of Gastrointestinal Surgery, Department of Surgery, College of Medicine, The Catholic University of Korea) ;
  • Hyeon, Ji Yeon (Department of Hospital Pathology, College of Medicine, The Catholic University of Korea) ;
  • Shin, Ok-Ran (Department of Hospital Pathology, College of Medicine, The Catholic University of Korea) ;
  • Lee, Han Hong (Division of Gastrointestinal Surgery, Department of Surgery, College of Medicine, The Catholic University of Korea)
  • Received : 2015.12.14
  • Accepted : 2015.12.23
  • Published : 2015.12.31
Download PDF
⟨ Previous Next ⟩

Abstract

C-kit-negative gastrointestinal stromal tumors (GISTs) are uncommon, and there have been few reports about the diagnosis and treatment of c-kit-negative GISTs in the stomach. We report the case of a patient who was diagnosed with a huge and atypical GIST in the stomach. The GIST was completely resected and finally diagnosed as c-kit-negative GIST based on immunohistochemical staining of tumor cells, which were negative for CD117 and CD34 and positive for Discovered on GIST-1 (DOG1). C-kit-negative GISTs could be treated by complete resection and/or imatinib, which is the same treatment for c-kit-positive GISTs.

Keywords

References

  1. Ducimetiere F, Lurkin A, Ranchere-Vince D, Decouvelaere AV, Peoch M, Istier L, et al. I. Incidence of sarcoma histotypes and molecular subtypes in a prospective epidemiological study with central pathology review and molecular testing. PLoS One 2011;6:e20294. https://doi.org/10.1371/journal.pone.0020294
  2. Nilsson B, Bumming P, Meis-Kindblom JM, Oden A, Dortok A, Gustavsson B, et al. Gastrointestinal stromal tumors: the incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era: a population-based study in western Sweden. Cancer 2005;103:821-829. https://doi.org/10.1002/cncr.20862
  3. Tran T, Davila JA, El-Serag HB. The epidemiology of malignant gastrointestinal stromal tumors: an analysis of 1,458 cases from 1992 to 2000. Am J Gastroenterol 2005;100:162-168. https://doi.org/10.1111/j.1572-0241.2005.40709.x
  4. Cho MY, Sohn JH, Kim JM, Kim KM, Park YS, Kim WH, et al. Current trends in the epidemiological and pathological characteristics of gastrointestinal stromal tumors in Korea, 2003-2004. J Korean Med Sci 2010;25:853-862. https://doi.org/10.3346/jkms.2010.25.6.853
  5. Hirota S, Isozaki K, Moriyama Y, Hashimoto K, Nishida T, Ishiguro S, et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 1998;279:577-580. https://doi.org/10.1126/science.279.5350.577
  6. Corless CL, Heinrich MC. Molecular pathobiology of gastrointestinal stromal sarcomas. Annu Rev Pathol 2008;3:557-586. https://doi.org/10.1146/annurev.pathmechdis.3.121806.151538
  7. Medeiros F, Corless CL, Duensing A, Hornick JL, Oliveira AM, Heinrich MC, et al. KIT-negative gastrointestinal stromal tumors: proof of concept and therapeutic implications. Am J Surg Pathol 2004;28:889-894. https://doi.org/10.1097/00000478-200407000-00007
  8. Joensuu H, Hohenberger P, Corless CL. Gastrointestinal stromal tumour. Lancet 2013;382:973-983. https://doi.org/10.1016/S0140-6736(13)60106-3
  9. Kang GH, Srivastava A, Kim YE, Park HJ, Park CK, Sohn TS, et al. DOG1 and PKC-$\theta$ are useful in the diagnosis of KIT-negative gastrointestinal stromal tumors. Mod Pathol 2011;24:866-875. https://doi.org/10.1038/modpathol.2011.11
  10. Espinosa I, Lee CH, Kim MK, Rouse BT, Subramanian S, Montgomery K, et al. A novel monoclonal antibody against DOG1 is a sensitive and specific marker for gastrointestinal stromal tumors. Am J Surg Pathol 2008;32:210-218. https://doi.org/10.1097/PAS.0b013e3181238cec
  11. Liegl B, Hornick JL, Corless CL, Fletcher CD. Monoclonal antibody DOG1.1 shows higher sensitivity than KIT in the diagnosis of gastrointestinal stromal tumors, including unusual subtypes. Am J Surg Pathol 2009;33:437-446. https://doi.org/10.1097/PAS.0b013e318186b158
  12. Miettinen M, Wang ZF, Lasota J. DOG1 antibody in the differential diagnosis of gastrointestinal stromal tumors: a study of 1840 cases. Am J Surg Pathol 2009;33:1401-1408. https://doi.org/10.1097/PAS.0b013e3181a90e1a
  13. Hohenberger P, Ronellenfitsch U, Oladeji O, Pink D, Ströbel P, Wardelmann E, et al. Pattern of recurrence in patients with ruptured primary gastrointestinal stromal tumour. Br J Surg 2010;97:1854-1859. https://doi.org/10.1002/bjs.7222
  14. Deshaies I, Cherenfant J, Gusani NJ, Jiang Y, Harvey HA, Kimchi ET, et al. Gastrointestinal stromal tumor (GIST) recurrence following surgery: review of the clinical utility of imatinib treatment. Ther Clin Risk Manag 2010;6:453-458. https://doi.org/10.2147/TCRM.S5634
  15. Blanke CD, Rankin C, Demetri GD, Ryan CW, von Mehren M, Benjamin RS, et al. Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. J Clin Oncol 2008;26:626-632. https://doi.org/10.1200/JCO.2007.13.4452
  16. Dematteo RP, Ballman KV, Antonescu CR, Maki RG, Pisters PW, Demetri GD, et al; American College of Surgeons Oncology Group (ACOSOG) Intergroup Adjuvant GIST Study Team. Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, doubleblind, placebo-controlled trial. Lancet 2009;373:1097-1104. https://doi.org/10.1016/S0140-6736(09)60500-6
  17. DeMatteo RP, Lewis JJ, Leung D, Mudan SS, Woodruff JM, Brennan MF. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg 2000;231:51-58. https://doi.org/10.1097/00000658-200001000-00008
  18. West RB, Corless CL, Chen X, Rubin BP, Subramanian S, Montgomery K, et al. The novel marker, DOG1, is expressed ubiquitously in gastrointestinal stromal tumors irrespective of KIT or PDGFRA mutation status. Am J Pathol 2004;165:107-113. https://doi.org/10.1016/S0002-9440(10)63279-8
  19. Dewar AL, Cambareri AC, Zannettino AC, Miller BL, Doherty KV, Hughes TP, et al. Macrophage colony-stimulating factor receptor c-fms is a novel target of imatinib. Blood 2005;105:3127-3132. https://doi.org/10.1182/blood-2004-10-3967

Cited by

  1. A very rare case of a small bowel leiomyosarcoma leading to ileocaecal intussusception treated with a laparoscopic resection: a case report and a literature review vol.14, pp.None, 2015, https://doi.org/10.1186/s12957-016-0798-4
  2. Gene expression analyses determine two different subpopulations in KIT-negative GIST-like (KNGL) patients vol.9, pp.25, 2018, https://doi.org/10.18632/oncotarget.24799
  3. C-kit-negative Extragastrointestinal Stromal Tumor Originating in the Mesentery Misdiagnosed as an Ovarian Tumor before Surgery vol.21, pp.2, 2015, https://doi.org/10.7704/kjhugr.2020.0061